• Alterity Therapeutics received a new U.S. composition-of-matter patent covering a crystalline form of ATH434 mesylate.
• Patent protection for ATH434 extends to at least 2045, strengthening long-term commercial exclusivity.
• Claims also cover methods of treating neurological conditions using the patented form.
• Company plans to use this form in a Phase 3 Multiple System Atrophy program targeted to start by year-end 2026.
• Expanded IP position supports potential development in Parkinson’s disease alongside Multiple System Atrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120705PRIMZONEFULLFEED9808373) on August 12, 2026, and is solely responsible for the information contained therein.